Influenza A m1 Inhibitors

1-Adamantylamine is an antiviral compound that targets the M2 ion channel of Influenza A. By blocking the ion channel, Amantadine disrupts the acidification of the virus particles in endosomes, preventing their release into the host cell cytoplasm and inhibiting the replication of the virus.

Rimantadine, similar to Amantadine, is an M2 ion channel inhibitor. It impedes the acidification of viral particles in endosomes, restricting the release of the viral genetic material into the host cell cytoplasm. This inhibition of the viral replication cycle contributes to the antiviral activity of Rimantadine.

Oseltamivir is a neuraminidase inhibitor that prevents the release of newly formed virions from infected cells. By inhibiting neuraminidase, Oseltamivir blocks the cleavage of sialic acid residues on the host cell surface, preventing the release of progeny viruses and limiting the spread of the infection.

Zanamivir, another neuraminidase inhibitor, acts by blocking the cleavage of sialic acid residues on the surface of infected host cells. This inhibition prevents the release of viral particles and curtails the spread of the infection. Zanamivir's mechanism contributes to its antiviral effects against Influenza A.

Peramivir is a neuraminidase inhibitor that impedes the release of new virions from infected cells. Similar to other neuraminidase inhibitors, Peramivir restricts the cleavage of sialic acid residues on the host cell surface, hindering the release of progeny viruses and limiting the spread of the infection.

Baloxavir Marboxil is an endonuclease inhibitor that disrupts the cap-dependent endonuclease activity of the viral polymerase. By inhibiting viral RNA synthesis, Baloxavir Marboxil impedes the replication of Influenza A virus. This unique mechanism of action distinguishes it from other antivirals and contributes to its efficacy.

Arbidol is an antiviral agent that targets the viral envelope and prevents the fusion of the viral membrane with the host cell membrane. By interfering with the fusion process, Arbidol inhibits the entry of the virus into host cells, limiting the establishment of infection and the subsequent viral replication of Influenza A.

Nitazoxanide is an antiparasitic and antiviral agent that exhibits broad-spectrum activity. It inhibits the maturation and release of viral particles by interfering with the hemagglutinin maturation process. This inhibition limits the spread of Influenza A virus within the host, contributing to the antiviral effects of Nitazoxanide.

Ribavirin is a broad-spectrum antiviral that interferes with viral RNA synthesis. By inhibiting the viral RNA-dependent RNA polymerase, Ribavirin disrupts viral replication. This action hampers the ability of Influenza A virus to produce functional RNA genomes, contributing to the overall inhibition of viral replication.

Camostat mesylate is a serine protease inhibitor that has been investigated for its potential antiviral activity. It inhibits the serine protease TMPRSS2, which is involved in the cleavage of the influenza virus hemagglutinin. By blocking this protease activity, Camostat Mesilate may impede viral entry and inhibit Influenza A infection.